KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial.

Wenjia Zuo, Zhonghua Wang, Jun Qian, Xiaopeng Ma, Zhaofeng Niu, Jianghua Ou, Qinguo Mo, Jing Sun, Xinzheng Li, Qitang Wang, Yongzhong Yao, Guohua Yu, Hongsheng Li, Dedian Chen, Hao Zhang, Cuizhi Geng, Guangdong Qiao, Mengmeng Zhao, Baihui Zhang, Xiaoyan Kang, Jin Zhang, Zhimin Shao

Br J Cancer 131(4) 668-675

PMID38906970
PMCIDPMC11333611
DOI10.1038/s41416-024-02751-2
发表日期2024-06-21
入排依据:The study is a Phase III randomized trial with a drug-containing intervention in oncology, but the primary efficacy endpoint is total pathologic complete response (tpCR), which is not a time-to-event endpoint. No time-to-event endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP), Kaplan-Meier analysis, or hazard ratio is reported. Therefore, it does not meet the inclusion criterion for a primary/key secondary time-to-event efficacy endpoint.
摘要

摘要

BACKGROUND: This randomized, parallel-controlled, double-blinded, phase III equivalence study evaluated the equivalence of a proposed pertuzumab biosimilar QL1209 to the pertuzumab (Perjeta®) each with trastuzumab and docetaxel in neoadjuvant treatment of early or locally advanced breast cancer patients with HER2-positive, ER/PR-negative. METHODS: Eligible patients were randomly (1:1) assigned to receive 4 cycles of neoadjuvant QL1209 or pertuzumab each with trastuzumab and docetaxel, and adjuvant treatment. The primary endpoint was total pathologic complete response (tpCR), with equivalence margins of 0.76 to 1.32. RESULTS: Among the 585 patients enrolled, 257 and 259 patients were assigned to the QL1209 and pertuzumab groups, respectively. The tpCR rates were comparable in the QL1209 (109/255, 42.75%; 90% CI 37.65 to 47.84) and pertuzumab (117/259, 45.17%; 90% CI 40.09 to 50.26) groups. The tpCR risk ratio was 0.95 (90% CI, 0.80 to 1.11), and the 90% CI fell within the predefined equivalence margin. The most common grade ≥3 treatment-related adverse event was decreased neutrophil count (10. 9% vs. 12.7%) in the QL1209 and pertuzumab groups. CONCLUSIONS: QL1209 demonstrated equivalent efficacy and comparable safety profile to the reference pertuzumab in neoadjuvant treatment of HER2-positive, ER/PR-negative, early, or locally advanced breast cancer. TRIAL REGISTRATION: Chinadrugtrials.org CTR20201073; ClinicalTrials.gov NCT04629846.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。